ArticleFrontiers in cardiovascular medicine2026
Development and validation of a prediction model for 1-year all-cause rehospitalisation after discharge in patients with heart failure with preserved ejection fraction based on the systemic immune-inflammation index.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and internally validate a practical model for predicting the risk of at least one all-cause rehospitalisation within 1 year after discharge in patients with heart failure with preserved ejection fraction (HFpEF), with particular attention to the systemic immune-inflammation index (SII). Methods: This single-center observational study was based on retrospective analysis of index-admission data and follow-up records from patients with HFpEF treated at Fuyang People's Hospital between January 2022 and January 2024. Among 341 initially eligible patients, 29 were lost to follow-up, leaving a final analytic cohort of 312 patients. The cohort was divided into a training set ( Results: LnSII, LnNT-proBNP, LnLp(a), GFR, and hypertension remained in the final model. The model showed good discrimination, with an area under the receiver operating characteristic curve of 0.8468 in the training set and 0.8302 in the validation set. At the optimal cutoff derived from the training set, sensitivity and specificity were 0.7101 and 0.8993 in the training set and 0.5333 and 0.8750 in the validation set, respectively. Calibration was acceptable in both cohorts according to the Hosmer-Lemeshow test, and decision curve analysis suggested potential clinical utility. Conclusion: A 5-variable model incorporating LnSII, LnNT-proBNP, LnLp(a), GFR, and hypertension showed good discrimination, acceptable calibration, and potential clinical usefulness for predicting 1-year all-cause rehospitalisation after discharge in patients with HFpEF. External validation is needed before broader application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.